{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-065184","form_type":"8-K","ticker":"OFIX","cik":"0000884624","company_name":"Orthofix Medical Inc.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.913667+00:00","generated_at":"2026-05-16T01:00:00.678553+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Orthofix Q4 net sales $219.9M, net loss narrows; FY26 guidance $850-860M sales, $95-98M adj. EBITDA","bullets":["Q4 net loss $(2.2)M vs $(29.1)M YoY; adjusted EBITDA $29.2M (13.4% margin), up 230 bps.","Full-year 2025 net sales $822.3M (+2.9% reported); pro forma $811.9M (+4.1% constant currency).","FY25 net loss $(92.2)M, improved from $(126.0)M; free cash flow $3.1M (ex-M6 restructuring).","2026 guidance: net sales $850-860M (~5.5% pro forma CC growth); adj. EBITDA $95-98M.","Three-year targets (2026-28): 6.5-7.5% sales CAGR, mid-teens EBITDA margin by 2028, positive FCF."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-065184","json":"https://secwatch.observer/filing/0001193125-26-065184.json","markdown":"https://secwatch.observer/filing/0001193125-26-065184.md","text":"https://secwatch.observer/filing/0001193125-26-065184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/884624/000119312526065184/0001193125-26-065184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/884624/000119312526065184/ofix-20260224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:00:00.678553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}